

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

EBC-1

RRID:CVCL_2891

Type: Cell Line

Proper Citation

RRID:CVCL_2891

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2891

Proper Citation: RRID:CVCL_2891

Description: Cell line EBC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:8286010](#), [PMID:9290701](#), [PMID:10358721](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:12569360](#), [PMID:14581340](#), [PMID:15185009](#), [PMID:15746151](#), [PMID:16105816](#), [PMID:17325662](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22313637](#), [PMID:22460905](#), [PMID:24002593](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28676216](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38639832](#)

Comments: Population: Chinese; Taiwan., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EBC-1

Synonyms: EBC-1/original, EBC1

Cross References: BTO:BTO_0003001, CLO:CLO_0050039, EFO:EFO_0003115, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:861, BioSample:SAMN03472045, BioSample:SAMN03472311, BioSample:SAMN10987674, cancercellines:CVCL_2891,

Cell_Model_Passport:SIDM00486, CGH-DB:185-1, CGH-DB:9172-4, ChEMBL-Cells:ChEMBL4295447, ChEMBL-Targets:ChEMBL4296411, CLS:305539, Cosmic:753554, Cosmic:801583, Cosmic:844845, Cosmic:876170, Cosmic:889089, Cosmic:917995, Cosmic:932929, Cosmic:946069, Cosmic:1048220, Cosmic:1219069, Cosmic:1239905, Cosmic:1571731, Cosmic:1656904, Cosmic:1694670, Cosmic:1802303, Cosmic:2060527, Cosmic:2125222, Cosmic:2546867, Cosmic:2645028, Cosmic:2668327, Cosmic-CLP:753554, DepMap:ACH-000563, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10486-107A9, GDSC:753554, GEO:GSM274671, GEO:GSM827595, GEO:GSM886993, GEO:GSM888062, GEO:GSM1374471, GEO:GSM1669749, IARC_TP53:11876, IARC_TP53:21134, JCRB:JCRB0820, LiGeA:CCLE_474, LINCS_LDP:LCL-1584, PharmacDB:EBC1_315_2019, PRIDE:PXD030304, Progenetix:CVCL_2891, PubChem_Cell_line:CVCL_2891, RCB:RCB1965, TKG:TKG 0481, Wikidata:Q54831756

ID: CVCL_2891

Record Creation Time: 20220427T215827+0000

Record Last Update: 20260829T232601+0000

Ratings and Alerts

No rating or validation information has been found for EBC-1.

No alerts have been found for EBC-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Nørregaard KS, et al. (2026) The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. *Molecular cancer therapeutics*, 25(1), 140.

Çak?lkaya P, et al. (2026) Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin. *Cancer research communications*, 6(1), 130.

Miglio U, et al. (2025) Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells. *Molecular therapy. Nucleic acids*, 36(2), 102529.

Mizusaki S, et al. (2025) NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors. *Cancer*

immunology, immunotherapy : CII, 74(7), 211.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. Cell reports, 43(1), 113598.

Kajtár M, et al. (2024) Competing Domino Knoevenagel-Cyclization Sequences with N-Arylcinnamylamines. The Journal of organic chemistry, 89(10), 6937.

Lim SM, et al. (2024) Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications, 4(7), 1748.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. Cell reports. Medicine, 4(12), 101302.

Kumata S, et al. (2023) Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer. Thoracic cancer, 14(21), 2057.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer cell, 41(1), 88.

Altintas DM, et al. (2022) The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. International journal of molecular sciences, 23(20).

Orlando E, et al. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(1), 6.

Horváti K, et al. (2021) Novel Assay Platform to Evaluate Intracellular Killing of Mycobacterium tuberculosis: In Vitro and In Vivo Validation. Frontiers in immunology, 12, 750496.

Kurppa KJ, et al. (2020) Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer cell, 37(1), 104.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell, 181(3), 702.